Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
about
Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionDraft versus finished sequence data for DNA and protein diagnostic signature developmentInhibition of the Hantavirus Fusion Process by Predicted Domain III and Stem Peptides from Glycoprotein GcRole of Marine Natural Products in the Genesis of Antiviral AgentsCurrent perspectives on HIV-1 antiretroviral drug resistanceAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡Structural and biological mimicry of protein surface recognition by / -peptide foldamersCrystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 InteractionStructural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41Broad Distribution of Energetically Important Contacts across an Extended Protein InterfaceBroad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideEnhancement of α-Helix Mimicry by an α/β-Peptide Foldamer via Incorporation of a Dense Ionic Side-Chain ArrayApproved Antiviral Drugs over the Past 50 YearsAccess denied? The status of co-receptor inhibition to counter HIV entryHIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranesConjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its actionA novel small-molecule inhibitor of HIV-1 entryA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroDevelopment of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors.Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cellsStructure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.Opportunities to minimise risk in drug discovery and development.Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibitionScreening for peptide drugs from the natural repertoire of biodiverse protein folds.A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutLong-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1.Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.Inhibition of murine leukemia virus envelope protein (env) processing by intracellular expression of the env N-terminal heptad repeat regionSystem to assess genome sequencing needs for viral protein diagnostics and therapeuticsAmino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitorA screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2Phenotypic screening of phylomer peptide libraries derived from genome fragments to identify and validate new targets and therapeutics.An anti-HIV microbicide comes alive
P2860
Q24316120-64E57618-10AA-440E-944D-00BF53B05FD7Q24816158-2C4D2935-589F-4D78-AD1B-8D767FCD1861Q26700097-D697BC88-BED8-4DF4-A854-A2C9FD743DA0Q26796360-7CBF9641-88AF-43D2-ADBE-5F9912461D7FQ26852626-FF061092-92FF-4034-8CEB-C28B0A256DC6Q27489000-0D861C39-A25B-4315-80B4-FF5F29E90640Q27653846-79ECA9AA-A8F6-4CBC-9C2B-714FD79ECAC1Q27657158-D2A87133-D574-4145-9530-1FD720F240E1Q27661588-0652AB5A-279A-467F-9F51-DD1BA7E71599Q27665960-76DE7F09-1C8D-4596-8A9C-E0E11A97DC14Q27666159-4EAB0463-EA94-45ED-9C22-E2C21B816244Q27666255-DFD5BB3A-278E-4E18-929E-9A867B387274Q27676641-7BEBF330-0DC2-4C95-A977-C241D22D8B36Q27678660-D04E6BF3-A3FC-47FF-9805-EA79A93E1721Q27755387-DD96A141-CEAD-450A-A86B-CC63FF8681E4Q28300187-98FF1794-9E69-4EC2-9986-CF48A96EE102Q28473380-2979745E-56B5-4AF3-95EE-246316D73B90Q28485911-73C1F813-44D5-4271-AAA3-220BCB3C1963Q28606625-65B22980-DDB8-4C54-8E32-D60DA7606EE3Q28728917-33B60235-A38B-4E92-BD0A-F3D2E691298AQ30351993-70A6D0A9-9E57-464D-8C85-CD08AD0C858DQ30357092-F825EC6F-4B16-47B0-93E3-E38A5883E35AQ30358736-442601EA-CF6F-48E7-AC37-138437625FF7Q30428283-3C0F6AF1-FBD5-479B-9A00-D4123AD162A3Q30493649-58DABF31-07DE-4771-A8F1-9B9D6770254DQ33233385-A655EF08-9C3F-4088-B9DA-942918EABB7CQ33300529-F2B6E631-C1F1-462F-89A1-DCDF8FD89514Q33312534-BA4A0127-FB2E-4406-8C82-2AABCF477A48Q33356323-1327E253-DA7C-443B-BDFA-59BA2A30A8DAQ33429777-1170C03D-E99A-446C-A332-66A58AFFFBD5Q33495440-DACF1925-B459-4C75-B832-9B57D15D5FD5Q33559031-FFABC61D-57B2-4706-93C8-B9D3284ECC56Q33595068-036C9ECE-1576-4AB9-9F18-4606D80F7824Q33686657-644F59D7-31D8-4A70-BFA1-E174A852262EQ33724327-01E7DCBA-0581-4682-8D50-76CC107775EEQ33753114-C5F2B9A4-3B65-403D-8210-76D1B8A83272Q33780643-850BDFCF-9E31-4938-9772-DAEC6FF57B0EQ33822543-09ABB98D-5BD1-4FF8-96CC-CC3F11D410F9Q33852350-07862B77-7B94-407D-A68F-45FD0E5A6CC5Q33934017-DD7196AA-A3D5-44FD-98EF-350CE5FD396A
P2860
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@ast
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@en
type
label
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@ast
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@en
prefLabel
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@ast
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@en
P2093
P356
P1476
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
@en
P2093
Dani Bolognesi
Jain Chung
Michael Greenberg
Miklos Salgo
Ralph DeMasi
Tom Matthews
P2888
P304
P356
10.1038/NRD1331
P577
2004-03-01T00:00:00Z